Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Org OD 14 and the endometrium.

A R Genazzani1, L J Benedek-Jaszmann, D M Hart

  • 1Department of Obstetrics and Gynaecology, University of Modena, Italy.

Maturitas
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.

Anticancer research·2001
Same author

Serum allopregnanolone in women with postpartum "blues".

Obstetrics and gynecology·2001
Same author

The use of a starting dose of recombinant follicle stimulating hormone for controlled ovarian hyperstimulation: a randomized pilot study.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
Same author

Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
Same author

Ovarian follicular fluid contains immunoreactive estriol: lack of correlation with estradiol concentrations.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
Same author

Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000

Tibolone (Org OD 14) therapy in post-menopausal women showed no significant endometrial changes. Endometrial patterns remained stable or atrophic, similar to untreated women, indicating a neutral effect.

Area of Science:

  • Endocrinology
  • Gynecology

Background:

  • Hormone therapy is common for post-menopausal symptoms.
  • Understanding the endometrial effects of tibolone is crucial for patient safety.

Purpose of the Study:

  • To evaluate the long-term influence of tibolone (Org OD 14) on the endometrium of post-menopausal women.

Main Methods:

  • Endometrial biopsies were collected from 39 post-menopausal women treated with 2.5 mg/day tibolone.
  • Treatment durations ranged from 3 months to 5 years and 11 months.
  • Data from 168 patients treated with Org OD 14 were reviewed.

Main Results:

  • 90% of patients showed no change in endometrial pattern during tibolone treatment.
  • Slight endometrial proliferation, similar to early cycle changes, occurred in 15 cases.

Related Experiment Videos

  • Many patients exhibited an atrophic endometrial pattern, with no tissue obtainable.

    • Conclusions:

    • Long-term tibolone therapy does not adversely affect the endometrium in post-menopausal women.
    • The endometrial response to tibolone is comparable to that of untreated post-menopausal women.
    • Tibolone appears to maintain a neutral or atrophic endometrial state.